Project Grant RF1NS136108
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$2.1M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...
This Project Grant award, totaling $444,125 and awarded by the National Institute of Neurological Disorders and Stroke (NINDS), is funding research under the Drug Use and Addiction Research Programs (CFDA 93.279) to explore the function of the LRRC55 protein in pain transmission. The primary recipient, Duke University, will investigate the role of LRRC55 in regulating ion channels involved in chronic pain, with the goal of identifying novel, non-opioid therapeutic targets to treat pain. Key...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to characterize the role of orexin neurons in the spinal cord and their influence on chronic pain transmission. The $158,512 award to the University of Pittsburgh will utilize two-photon calcium imaging and chemogenetic techniques to investigate how...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into a novel, non-opioid spinal analgesic mechanism for the treatment of high-impact chronic pain. The $664,772 award to the University of Texas Southwestern Medical Center aims to dissect the signaling pathway involving the neurotensin receptor 2 (NTSR2)...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
This $675,107 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is supporting research conducted by Northeastern University to develop novel, non-opioid, and non-addictive analgesics for treating neuropathic pain. The primary objectives are to design and synthesize a series of new "dualsteric modulators" that act as both non-psychoactive...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $945,966 to Rowan University to research the potential of the GPR83 pathway as a target for reducing the abuse liability of opioid medications. The key objectives are to: Determine the physical interactions between the neuropeptide PEN-activated GPR83 receptor and the mu-opioid receptor (MOR) in the periaqueductal gray region of the brain. Define...
The National Institute on Drug Abuse (NIDA) awarded a $118,457 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant period runs from April 15, 2025 to March 31, 2026. The objective of this project is to elucidate the genetic architecture and underlying mechanisms of chronic pain in order to inform the development of novel,...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-addictive analgesic treatment for chronic ocular pain. The $1,559,917 grant awarded to The Schepens Eye Research Institute, Inc. will fund research to assess the efficacy of a topical neurokinin-1 receptor (NK1R) antagonist in suppressing chronic ocular pain and modulating the ocular surface-trigeminal...